• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Research
  1. UPDATE: Four reasons for investors to buy biotechnology stocks now

    UPDATE: Four reasons for investors to buy biotechnology stocks now

  2. Relapsing Remitting Multiple Sclerosis (RRMS) Pipeline Report, H1 2016 - Review of 26 Companies & Drug Profiles - Research and Markets

    Relapsing Remitting Multiple Sclerosis (RRMS) Pipeline Report, H1 2016 - Review of 26 Companies & Drug Profiles - Research and Markets

  3. Fitch Rates Amgen Inc. Notes Offering 'BBB'; Outlook Stable

    Fitch Rates Amgen Inc. Notes Offering 'BBB'; Outlook Stable

  4. Global Contract Pharmaceutical Manufacturing Market Worth $84 Billion by 2020 - Increasing Demand for Generic Drugs - Research and Markets

    Global Contract Pharmaceutical Manufacturing Market Worth $84 Billion by 2020 - Increasing Demand for Generic Drugs - Research and Markets

  5. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  6. A Preview of the 2014 Morningstar International-Stock Fund Manager of the Year Competition

    These managers are potential contenders for this year's honor.

  7. Our Outlook for the Credit Markets

    Widening investment-grade credit spreads and rising interest rates lead to losses.

  8. Credit Market Outlook: Tight Spreads Will Keep a Lid on Returns

    As credit spreads have tightened on a nearly continuous trend over the past year, they are becoming richly valued relative to their historical average.

  9. Actavis' Wide-Moat Transformation Offers Shareholder Rewards

    Product durability, diversification, and cost synergies support strong earnings growth for this undervalued wide-moat firm.

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.